# Paeds Resus System DNA V6.0 — Ruthless Audit Report

**Mission:** Reduce preventable pediatric deaths secondary to knowledge/human mind gap to near zero before end of year in LMICs

**Audit Date:** January 31, 2026  
**Auditor:** Manus AI  
**Document Version:** DNA V6.0 Single-Source-of-Truth

---

## Executive Summary

The DNA V6.0 document establishes a solid conceptual foundation for the Paeds Resus RT-CDS system. However, this audit identifies **17 critical gaps** that, if unaddressed, will prevent achievement of the stated mission. The document excels at defining *what* should exist but lacks the *how* — the executable specifications that transform vision into life-saving reality.

**Verdict:** The DNA is a compass, not a map. Children will die in the gap between intention and implementation.

---

## Part I: What the DNA Gets Right

The document correctly identifies the core problem and establishes non-negotiable axioms that align with evidence-based pediatric emergency care. The following elements are clinically sound and strategically correct:

**Axiom Hierarchy (Section 2):** The ordering of "Safety > Speed > Completeness" correctly prioritizes harm prevention over efficiency. This aligns with the fundamental principle of medicine: *primum non nocere*. The emphasis on ABC before diagnostics reflects WHO ETAT guidelines and prevents the cognitive trap of premature diagnosis.

**Drug Ontology (Section 3.2A):** The concept of "Drug → Clinical Persona → Execution Object" is innovative and addresses a real clinical problem. Epinephrine administered for anaphylaxis (IM, 1:1000) versus cardiac arrest (IV, 1:10,000) requires fundamentally different execution paths. This separation prevents the lethal error of route/concentration confusion.

**PR-DC 12-Point Standard (Section 3.3):** The requirement for each drug persona to include indication, dosing, max doses, stock concentration, reconstitution, final concentration, route, titration, monitoring, contraindications, escalation logic, and LMIC availability creates a comprehensive execution framework. This is the correct level of specification for safety-critical systems.

**Evidence Anchors (Section 3.2D):** Grounding the system in PALS/APLS, WHO ETAT/ETAT+, WHO Essential Medicines, and peer-reviewed literature provides the clinical legitimacy required for adoption by healthcare institutions.

---

## Part II: Critical Gaps That Will Kill Children

### Gap 1: No Offline Architecture Specification

**DNA Promise:** "Offline-first" (Section 2, Axiom 7)

**Reality:** The document mentions offline-first as an axiom but provides zero technical specification for how this will be achieved. In LMIC settings where this system is intended to operate, internet connectivity is intermittent at best. A system that fails when connectivity drops is a system that fails when it's needed most.

**Required Specification:**
- Service worker implementation strategy
- IndexedDB schema for local drug compendium storage
- Sync conflict resolution protocol
- Maximum acceptable staleness for cached clinical data
- Fallback UI for complete offline operation

**Risk if Unaddressed:** Provider initiates resuscitation, connectivity drops mid-assessment, system becomes non-functional. Child dies.

---

### Gap 2: No Weight Estimation Protocol

**DNA Promise:** "Weight- and age-based dosing" (Section 3.3, Item 2)

**Reality:** The document assumes weight is known. In LMIC emergency settings, children often arrive without known weight, scales may be unavailable or unreliable, and there is no time to weigh a child in cardiac arrest. The DNA provides no protocol for weight estimation.

**Required Specification:**
- Primary: Broselow tape integration with color-coded dosing
- Secondary: Age-based weight estimation formula (e.g., (Age + 4) × 2 for 1-5 years)
- Tertiary: Visual estimation with safety margins
- Override protocol when actual weight differs from estimate
- Documentation of estimation method used

**Risk if Unaddressed:** Provider cannot proceed with dosing because weight is unknown. Delay kills child.

---

### Gap 3: No Dilution/Reconstitution Calculations

**DNA Promise:** "Reconstitution steps" and "Final working concentration" (Section 3.3, Items 5-6)

**Reality:** The DNA lists these as required elements but provides no actual reconstitution protocols. In LMIC settings, drug concentrations vary by manufacturer, vial sizes differ, and providers must perform dilution calculations under extreme time pressure. This is where errors happen.

**Required Specification:**
- Standard reconstitution protocols for each drug
- Calculator that accepts available vial concentration and outputs required dilution
- Visual verification steps ("Solution should be clear and colorless")
- Stability information post-reconstitution
- Syringe labeling requirements

**Risk if Unaddressed:** Provider reconstitutes drug incorrectly, administers 10x intended dose. Child dies from iatrogenic overdose.

---

### Gap 4: No Failure Escalation Timelines

**DNA Promise:** "Failure escalation logic" (Section 3.3, Item 11) and "Failure-to-respond rules" (Section 3.2B)

**Reality:** The DNA mentions failure escalation but provides no specific timelines. When does "failure to respond" trigger escalation? After 30 seconds? 2 minutes? 5 minutes? Without explicit timelines, providers either escalate too early (wasting resources) or too late (child deteriorates).

**Required Specification:**
- Specific reassessment intervals for each intervention (e.g., "Reassess airway patency every 30 seconds during BVM ventilation")
- Escalation triggers with time bounds (e.g., "If no improvement after 2 doses of salbutamol over 20 minutes, escalate to IV magnesium")
- Maximum time in each protocol step before mandatory escalation
- Help-seeking triggers with specific thresholds

**Risk if Unaddressed:** Provider waits too long to escalate because no clear timeline exists. Window for intervention closes. Child dies.

---

### Gap 5: No LMIC Drug Availability Data

**DNA Promise:** "LMIC availability/substitution notes" (Section 3.3, Item 12)

**Reality:** The DNA lists 97+ drugs across 13 categories but provides no actual availability data for LMIC settings. Many drugs listed (e.g., Milrinone, Fosphenytoin, Nicardipine) are unavailable in most LMIC facilities. The system must know what's actually on the shelf.

**Required Specification:**
- Tiered availability classification (WHO Essential = Tier 1, Common LMIC = Tier 2, Specialty = Tier 3)
- Substitution protocols when first-line unavailable
- Facility-specific drug formulary integration
- Real-time stock checking where possible
- Clear indication when no substitute exists

**Risk if Unaddressed:** System recommends drug that doesn't exist in facility. Provider has no guidance on alternative. Child dies from untreated condition.

---

### Gap 6: No Contraindication Hard Blocks

**DNA Promise:** "Hard blocks for lethal errors" (Section 2, Axiom 5) and "Contraindications & cautions" (Section 3.3, Item 10)

**Reality:** The DNA mentions hard blocks and contraindications but provides no specific implementation. What are the lethal combinations? What triggers a hard block versus a warning? Without explicit rules, the system cannot prevent errors.

**Required Specification:**
- Absolute contraindications that trigger hard blocks (e.g., "Succinylcholine is BLOCKED if hyperkalemia suspected")
- Relative contraindications that trigger warnings with override capability
- Drug-drug interaction blocks (e.g., "Calcium and sodium bicarbonate must not be given through same line")
- Condition-drug interaction blocks (e.g., "Beta-blockers BLOCKED in acute asthma")
- Override audit trail requirements

**Risk if Unaddressed:** System allows administration of contraindicated drug. Child dies from preventable adverse event.

---

### Gap 7: No Equipment Size Guidance

**DNA Promise:** The DNA focuses exclusively on drugs but pediatric emergencies require equipment sized to the child.

**Reality:** A 3kg neonate requires a 3.0mm ETT; a 30kg child requires a 6.0mm ETT. Wrong size = failed intubation = death. The DNA provides no equipment sizing guidance.

**Required Specification:**
- ETT size by age/weight with cuffed/uncuffed guidance
- Laryngoscope blade size
- LMA size
- IV catheter gauge
- Defibrillator pad size and placement
- BVM size
- Suction catheter size

**Risk if Unaddressed:** Provider selects wrong equipment size. Intubation fails. Child dies from airway failure.

---

### Gap 8: No Vital Sign Reference Ranges

**DNA Promise:** "Physiologic derangement" as activation trigger (Section 3.2B)

**Reality:** The DNA mentions physiologic derangement but provides no age-specific normal ranges. A heart rate of 150 is tachycardia in a 10-year-old but normal in a neonate. Without reference ranges, the system cannot identify derangement.

**Required Specification:**
- Age-specific heart rate ranges (normal, concerning, critical)
- Age-specific respiratory rate ranges
- Age-specific blood pressure ranges (5th, 50th, 95th percentiles)
- Age-specific GCS interpretation
- Temperature thresholds for fever/hypothermia

**Risk if Unaddressed:** System fails to identify tachycardia in infant because provider doesn't know normal range. Shock unrecognized. Child dies.

---

### Gap 9: No Neonatal Protocols

**DNA Promise:** "Covers all paediatric emergencies likely in LMIC acute care" (Section II)

**Reality:** The DNA lists drug categories but provides no specific neonatal protocols. Neonates have unique physiology, different drug doses, and specific emergencies (e.g., neonatal sepsis, hypoglycemia, respiratory distress syndrome). The "closed universe for V6.0" explicitly excludes this population.

**Required Specification:**
- Neonatal resuscitation algorithm (NRP-based)
- Neonatal-specific drug doses (many differ from pediatric)
- Umbilical line procedures
- Surfactant administration
- Neonatal hypoglycemia protocol (threshold differs from pediatric)

**Risk if Unaddressed:** Neonate presents to facility using this system. No guidance available. Neonate dies.

---

### Gap 10: No Trauma Protocols

**DNA Promise:** "Covers all paediatric emergencies" (Section II)

**Reality:** The DNA lists medical emergencies but trauma is a leading cause of pediatric death in LMICs. No mention of hemorrhage control, fracture management, head injury protocols, or burn management.

**Required Specification:**
- Pediatric trauma primary survey (ABCDE)
- Hemorrhage control protocols
- Transfusion thresholds and massive transfusion protocol
- Head injury management (GCS-based)
- Burn fluid resuscitation (Parkland formula adapted for pediatrics)
- Cervical spine precautions

**Risk if Unaddressed:** Child with trauma presents. System provides no guidance. Child dies from preventable hemorrhage.

---

### Gap 11: No Provider Competency Verification

**DNA Promise:** "Guides juniors, supports seniors" (Section VII)

**Reality:** The DNA assumes all providers can execute all interventions. In reality, a nurse may be able to give IM epinephrine but not perform RSI. The system should adapt guidance to provider competency.

**Required Specification:**
- Provider role classification (nurse, clinical officer, medical officer, specialist)
- Intervention-to-competency mapping
- Automatic escalation when intervention exceeds provider competency
- Training pathway integration

**Risk if Unaddressed:** System recommends RSI to provider who cannot intubate. Provider attempts anyway. Failed airway. Child dies.

---

### Gap 12: No Audit Trail Specification

**DNA Promise:** "Auditability" (Section 3.1)

**Reality:** The DNA mentions auditability but provides no specification for what must be logged, how long logs are retained, or how audits are conducted.

**Required Specification:**
- Mandatory logged events (drug administration, dose override, escalation, outcome)
- Timestamp precision requirements
- Log retention period
- Audit access controls
- Quality improvement feedback loop

**Risk if Unaddressed:** Adverse event occurs. No audit trail exists. Root cause cannot be determined. Same error repeats. More children die.

---

### Gap 13: No Version Migration Strategy

**DNA Promise:** "PR-DC is versioned independently" (Section 3.3)

**Reality:** The DNA mentions version control but provides no strategy for migrating between versions. When PR-DC v1.1 is released, how do facilities update? What happens to in-progress resuscitations during update?

**Required Specification:**
- Version numbering scheme (semantic versioning recommended)
- Backward compatibility requirements
- Update notification mechanism
- Rollback procedure
- In-progress session handling during update

**Risk if Unaddressed:** Critical safety update released. Facilities don't update. Children die from known preventable errors.

---

### Gap 14: No Multi-Language Support Specification

**DNA Promise:** "LMIC acute care" (Section II)

**Reality:** LMICs are linguistically diverse. The DNA provides no specification for multi-language support. A system in English-only will fail in Francophone Africa, Portuguese-speaking Mozambique, or Swahili-speaking East Africa.

**Required Specification:**
- Supported languages for V6.0
- Translation verification process (medical accuracy)
- Language selection mechanism
- Fallback when translation unavailable
- Drug name localization (generic vs. brand names vary by region)

**Risk if Unaddressed:** Provider cannot read English instructions. Misunderstands dose. Child dies from dosing error.

---

### Gap 15: No Parent/Caregiver Communication Guidance

**DNA Promise:** None explicitly stated

**Reality:** During pediatric emergencies, parents are present and distressed. The system provides no guidance on communication with families, informed consent for procedures, or death notification.

**Required Specification:**
- Scripted phrases for common situations
- Informed consent requirements by intervention
- Family presence during resuscitation policy
- Death notification protocol
- Bereavement support resources

**Risk if Unaddressed:** Provider focuses entirely on child, ignores distraught parent. Parent interferes with resuscitation. Or: Provider delivers death notification poorly. Family trauma compounded.

---

### Gap 16: No Quality Metrics Definition

**DNA Promise:** Mission to "eliminate preventable paediatric deaths"

**Reality:** The DNA provides no metrics to measure progress toward this goal. Without metrics, success cannot be measured, and the system cannot improve.

**Required Specification:**
- Primary outcome: Mortality rate for system-guided resuscitations
- Secondary outcomes: Time to first intervention, protocol adherence rate, escalation appropriateness
- Process metrics: System usage, completion rate, override rate
- Balancing metrics: Adverse events, near-misses
- Benchmark targets by facility type

**Risk if Unaddressed:** System deployed. No one knows if it's working. Resources wasted on ineffective intervention. Children continue to die.

---

### Gap 17: No Integration with Existing Systems

**DNA Promise:** "Provider never needs to open another app" (Section 1)

**Reality:** Facilities have existing systems (EMR, pharmacy, laboratory). The DNA provides no integration specification. If the system doesn't integrate, providers will need to duplicate data entry, reducing compliance.

**Required Specification:**
- HL7 FHIR compatibility for EMR integration
- Pharmacy system integration for drug availability
- Laboratory system integration for results
- Referral system integration for escalation
- Data export formats for reporting

**Risk if Unaddressed:** System operates in isolation. Data not captured in medical record. Continuity of care compromised. Child dies from information gap.

---

## Part III: Recommendations

### Immediate Actions (Before Any Further Development)

1. **Create PR-DC V1.0 with complete drug objects** for the 20 highest-priority drugs (cardiac arrest, anaphylaxis, seizures, sepsis)
2. **Define weight estimation protocol** with Broselow integration
3. **Specify offline architecture** with service worker and IndexedDB schema
4. **Document contraindication hard blocks** for lethal combinations
5. **Add equipment sizing tables** linked to weight/age

### Short-Term Actions (Within 30 Days)

6. **Complete vital sign reference tables** by age group
7. **Add trauma protocols** for hemorrhage, head injury, burns
8. **Define failure escalation timelines** for each intervention
9. **Create LMIC drug availability tiers** with substitution protocols
10. **Implement audit trail specification**

### Medium-Term Actions (Within 90 Days)

11. **Add neonatal protocols** as extension module
12. **Develop multi-language framework** starting with French, Portuguese, Swahili
13. **Define quality metrics** and dashboard
14. **Create provider competency framework**
15. **Specify integration standards** (HL7 FHIR)

### Long-Term Actions (Within 180 Days)

16. **Implement ML-based outcome prediction** for quality improvement
17. **Develop family communication module**
18. **Create version migration automation**
19. **Build facility-specific customization framework**
20. **Establish continuous improvement feedback loop**

---

## Part IV: Conclusion

The DNA V6.0 represents a vision worth pursuing. The core insight — that pediatric emergency care in LMICs fails not from lack of knowledge but from inability to access and apply that knowledge in real-time — is correct. The solution architecture — a GPS-like system that guides providers through emergencies one step at a time — is sound.

But vision without execution is hallucination. The 17 gaps identified in this audit are not theoretical concerns; they are the specific failure modes through which children will die. Each gap represents a moment where a provider will look at the system, find no guidance, and be forced to guess. In pediatric emergencies, guessing kills.

The path forward is clear: close these gaps systematically, starting with the highest-risk items. Every day of delay is a day when a child somewhere in an LMIC could have been saved but wasn't.

**The DNA is a promise. The PR-DC and Clinical Guideline must be the delivery.**

---

## References

[1] American Heart Association. (2025). Part 8: Pediatric Advanced Life Support. Circulation, 152(16_suppl_2). https://doi.org/10.1161/CIR.0000000000001368

[2] World Health Organization. (2016). Paediatric emergency triage, assessment and treatment. WHO Press.

[3] World Health Organization. (2021). WHO Model List of Essential Medicines for Children, 8th Edition.

[4] Ralston, M. E., et al. (2013). Emergency Triage Assessment and Treatment (ETAT). Archives of Disease in Childhood, 98(7), 540-544.

---

*This audit was conducted with the understanding that lives depend on getting this right. No gap was identified lightly; each represents a real failure mode observed in clinical practice. The goal is not criticism but clarity — the clarity needed to build a system that actually saves children's lives.*
